Frameworks For Enhanced Analytics in the Pharmaceutical Industry in The United Kingdom

Synopsis

The UK top 10 R&D investing companies (which have some subsidiaries around the world) invested €17.4 billion in pharmaceutical manufacturing, and the top two UK-based firms belong to the pharmaceuticals sector, with GSK and AstraZeneca respectively ranking 29 and 31 worldwide in 2020. In March 2020, the UK government committed to the creation of the Advanced Research and Invention Agency (ARIA) which is an independent research body to fund high-risk, high-reward scientific research. Besides, data analytics, digital tools and digital transformation can help to establish collaborations with external stakeholders (including patients, academia, non-governmental organisations and industry) and with international regulatory authorities on ‘Big Data’ initiatives. Thanks to such digital technologies, data can be managed and analysed within a secure and ethical governance framework. However, it is necessary to understand the latest advancements and problems when utilising enhanced data analytics for pharmaceutical safety and authenticity in order to optimise the system operation and consumer trust. Enhanced data analytics methods and their current applications in the UK pharmaceutical industry should be evaluated to establish an initial approachable framework. There are a variety of international and national regulations about data sharing and collaboration in pharmaceutical sectors, particularly about safety and authenticity. Although many data analyses can be used to support and maintain the interests and trust in UK’s consumers, it is hard to monitor the effective the translation into good practices due to different concerns. Therefore, the project focuses on relevant regulations-standards related to the pharmaceutical supply chain with the support of data analytics, and case studies of opportunities and challenges before offering potential suggestions.